Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin-Transdrug in Advanced Hepatocellular Carcinoma
2006-004088-77Phase 2Terminated
- Sponsor
- Valerio Therapeutics
- Start
- Aug 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Valerio Therapeutics. Primary endpoint: Primary endpoint (phase 2). Started Aug 2007; status: terminated.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2006-004088-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004088-77.